Rinvoq Tablet, Extended Release
Product Images NDC 0074-2310

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Rinvoq (NDC 0074-2310). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Abbvie Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Rinvoq 01

Chemical structure diagram of Upadacitinib, the active ingredient in Rinvoq. The diagram shows the molecular framework including specific ring systems and functional groups characteristic of Upadacitinib.*

FDA Label Image

Rinvoq 02

A line graph comparing the percent of responders over 14 weeks between two groups: Rinvoq 15 mg with methotrexate (MTX) and placebo with MTX. The X-axis represents weeks, and the Y-axis represents percent responders, showing higher and increasing response rates for Rinvoq + MTX compared to placebo + MTX.*

FDA Label Image

Rinvoq 03

A line graph comparing the percent responders over 12 weeks between Rinvoq 15 mg and placebo groups. The y-axis shows percent responders, and the x-axis shows time in weeks. The Rinvoq group shows a higher and steadily increasing response compared to the placebo group, which remains lower and plateaus around week 8.*

FDA Label Image

Rinvoq 04

A dual-panel line graph comparing response rates over 16 weeks in two clinical trials (Trial AD-1 and Trial AD-2) for Rinvoq extended-release tablets at 15 mg and 30 mg dosages daily versus placebo. The y-axis shows response rate percentage, and the x-axis shows time in weeks, illustrating increases over time for both Rinvoq doses compared to placebo.*

FDA Label Image

Rinvoq 05

A line graph showing response rates (%) over 16 weeks for three groups: Placebo + TCS, Rinvoq 15 mg QD + TCS, and Rinvoq 30 mg QD + TCS. Both Rinvoq doses show higher and stable response rates after week 4 compared to placebo, with Rinvoq 30 mg having the highest response rate.*

FDA Label Image

Rinvoq 06

A line graph depicting percent responders over a period of 14 weeks for Rinvoq 15 mg compared to placebo. The X-axis represents weeks, and the Y-axis shows percent responders, with Rinvoq demonstrating a higher response rate than placebo throughout the study duration.*

FDA Label Image

Rinvoq 07

Packaging label for Rinvoq 15 mg extended-release oral tablets by AbbVie Inc. The carton contains 30 tablets with instructions to dispense in original packaging. The label includes directions for opening and puncturing foil, a barcode, and contact information for Rinvoq customer support.*

FDA Label Image

Rinvoq 08

Rinvoq 15 mg extended-release tablets packaging label by AbbVie Inc. The label indicates it contains 14 tablets and is marked as a professional sample not for sale. The packaging includes instructions to dispense in the original packaging, with a visual of a tablet and a foil cutting tool infographic labeled for puncturing instructions. The label also shows the NDC number 0074-2306-70 and states the product is for oral use.*

FDA Label Image

Rinvoq 09

Rinvoq 30 mg extended-release tablets packaging label for oral use. The label features the brand and generic name Upadacitinib, with dosage strength prominently displayed. It includes usage instructions, a foil cutting tool guide, and contact information for customer support. The labeler is AbbVie Inc., and the package contains 30 tablets in the original dispensing container.*

FDA Label Image

Rinvoq 0a

Rinvoq 30 mg extended-release oral tablets packaging label from AbbVie Inc. The label indicates it is a professional sample not for sale and includes dosing instructions. The box design displays the product name, upadacitinib as the active ingredient, a dosage strength of 30 mg, 14 tablets count, and storage instructions. Additional information includes a foil cutting tool illustration and contact information for customer support.*

FDA Label Image

Rinvoq 0b

Rinvoq 45 mg extended-release tablets packaging label, featuring the product name, Upadacitinib as the active ingredient, and dosage strength of 45 mg. The label includes dosing instructions, a barcode, and contact information for AbbVie Inc., the labeler. The carton design indicates 28 tablets per package and shows instructions for puncturing foil and dispensing with a medication guide.*

FDA Label Image

Rinvoq 0c

Packaging label for Rinvoq 45 mg extended-release tablets by AbbVie Inc. The label shows the product name Rinvoq with the active ingredient Upadacitinib, specifying 45 mg strength and oral extended-release tablet form. It includes instructions to dispense in the original packaging with the enclosed medication guide, a professional sample notice, and directions for opening with a foil cutting tool. The label also features the NDC number, barcode, and the AbbVie logo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.